🍎🍎🍎 Gracie Barra BJJ 🟥⬛️⬛️⬛️🟥
Florida, USA
Joined July 2022
- Tweets9.7K
- Following5.3K
- Followers1.9K
- Likes33.5K
Supplements Manufacturer 🐊🐊🐊 retweeted
$ocgn does anyone else really compare Ocugen?
Not really, the industry is full of single asset gene therapy companies trying to secure a niche and maybe make a billion.
A good comparison is to look back at early Vertex/early Regeneron. Those were platform companies that built dominance around a biological insight that could be applied across multiple indications.
Ocugen isn’t a single asset gene therapy company. They aren’t chasing one mutation. They’re a platform company. Their nuclear hormone receptor platform regulates an entire genetic network connected to countless diseases. OCU400 is what will prove this biological insight. It won’t just mean one product approval, it validates the platform.
Ocugen has 3 BLAs lined up over the next two years. Manufacturing in place, commercial supply stored, strategic global partnerships, and patents filed to later expanding the platform, neurodegenerative diseases patents, including four Alzheimer’s patents.
This isn’t some niche ophthalmology company. It’s a vertically integrated gene therapy company with repeatable applications across massive unmet markets, at a time when regulatory pathways are evolving to fast track these exact kinds of indications.
If data continues like it has, we’re looking at the next big pharma without a doubt. And the revenue Ocugen is staring at likely means future forward splits, dividends, and buybacks.
The question isn’t “who do we become?” It’s what is a validated gene agnostic modifier platform worth? And I can tell you, its future is worth a hell of a lot more than Vertex and Regeneron combined. 🍻
Supplements Manufacturer 🐊🐊🐊 retweeted
Dry AMD can affect central vision over time. Geographic atrophy (GA) is an advanced form of #dryAMD. Ocugen’s #OCU410 is an investigational one-time gene therapy in Phase 3 for GA.
Notice changes in your vision? Speak with your eye care specialist. #EyeHealth
Supplements Manufacturer 🐊🐊🐊 retweeted
$ocgn does anyone else really compare Ocugen?
Not really, the industry is full of single asset gene therapy companies trying to secure a niche and maybe make a billion.
A good comparison is to look back at early Vertex/early Regeneron. Those were platform companies that built dominance around a biological insight that could be applied across multiple indications.
Ocugen isn’t a single asset gene therapy company. They aren’t chasing one mutation. They’re a platform company. Their nuclear hormone receptor platform regulates an entire genetic network connected to countless diseases. OCU400 is what will prove this biological insight. It won’t just mean one product approval, it validates the platform.
Ocugen has 3 BLAs lined up over the next two years. Manufacturing in place, commercial supply stored, strategic global partnerships, and patents filed to later expanding the platform, neurodegenerative diseases patents, including four Alzheimer’s patents.
This isn’t some niche ophthalmology company. It’s a vertically integrated gene therapy company with repeatable applications across massive unmet markets, at a time when regulatory pathways are evolving to fast track these exact kinds of indications.
If data continues like it has, we’re looking at the next big pharma without a doubt. And the revenue Ocugen is staring at likely means future forward splits, dividends, and buybacks.
The question isn’t “who do we become?” It’s what is a validated gene agnostic modifier platform worth? And I can tell you, its future is worth a hell of a lot more than Vertex and Regeneron combined. 🍻
$ocgn does anyone else really compare Ocugen?
Not really, the industry is full of single asset gene therapy companies trying to secure a niche and maybe make a billion.
A good comparison is to look back at early Vertex/early Regeneron. Those were platform companies that built dominance around a biological insight that could be applied across multiple indications.
Ocugen isn’t a single asset gene therapy company. They aren’t chasing one mutation. They’re a platform company. Their nuclear hormone receptor platform regulates an entire genetic network connected to countless diseases. OCU400 is what will prove this biological insight. It won’t just mean one product approval, it validates the platform.
Ocugen has 3 BLAs lined up over the next two years. Manufacturing in place, commercial supply stored, strategic global partnerships, and patents filed to later expanding the platform, neurodegenerative diseases patents, including four Alzheimer’s patents.
This isn’t some niche ophthalmology company. It’s a vertically integrated gene therapy company with repeatable applications across massive unmet markets, at a time when regulatory pathways are evolving to fast track these exact kinds of indications.
If data continues like it has, we’re looking at the next big pharma without a doubt. And the revenue Ocugen is staring at likely means future forward splits, dividends, and buybacks.
The question isn’t “who do we become?” It’s what is a validated gene agnostic modifier platform worth? And I can tell you, its future is worth a hell of a lot more than Vertex and Regeneron combined. 🍻
Supplements Manufacturer 🐊🐊🐊 retweeted
🚨: Stanford scientists removed the 'sugar shield' that protects cancer cells from being attacked
Tumors don't just grow: they hide. They coat its surface with sugar molecules that cheat the immune system and pass it by as if there were no threat.
#JiuJitsu 💥💥💥
Over time, the focus changed. Teaching stopped being primarily about the instructor’s own goals and started centering on the students — their progress, confidence, safety, learning, and growth.
The reward shifted from personal improvement or paycheck to seeing others succeed, struggle, improve, and sometimes transform through the art.
This is a very common experience among jiu-jitsu (and martial arts) instructors. What starts as something done for yourself often turns into a form of service and responsibility once you see the real impact on the people in front of you.
Supplements Manufacturer 🐊🐊🐊 retweeted
$OCGN #OCUGEN #OCU400
12 months and 3 yrs data for #OCU400
is mind-boggling.....
I believe this will be in medical journals soon enough. Public needs to know, especially the rare disease patients must have a treatment available to them.
We can not give up on them, bc it might be us tomorrow.
